Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Galera Therapeutics Inc (Galera Therapeutics) is a biopharmaceutical company that develops and commercializes novel mechanism-based therapies to transform radiotherapy in cancer treatment. It focuses on small-molecule superoxide dismutase (SOD) mimetics and a pan-nitric oxide synthase (NOS) inhibitor to enhance radiotherapy in cancer, by reducing severe oral mucositis (SOM). The company’s pipeline products include Tilarginine + nab-paclitaxel +PI3Ki which treats metaplastic breast cancer(TNBC); Tilarginine + paclitaxel for the treatment of triple negative breast cancer Avasopasem + (fulvestrant +CDK4/6i) that targets metastatic breast cancer and Tilarginine + taxane which treats Metastatic and locally advanced triple negative breast cancer. Galera Therapeutics is headquartered in Malvern, Pennsylvania, the US.
Headquarters
United States of America
Address
Suite 225, 101 Lindenwood Drive, Malvern, Pennsylvania, 19355
Website
www.galeratx.com
Telephone
1 844 4425372
No of Employees
3
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GRTX (OTC)
EPS
XYZ
Net Income (2025)
XYZ
886.2%
(2025 vs 2024)
Market Cap*
$17.9M
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| Tilarginine + nab-paclitaxel +PI3Ki: Metaplastic Breast Cancer |
| Tilarginine + paclitaxel: Triple Negative Breast Cancer (TNBC) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company signed an asset purchase agreement with Biossil to sell its dismutase mimetics portfolio. |
| 2024 | Acquisitions/Mergers/Takeovers | In December, the company acquired Nova Pharmaceuticals, Inc., a biotechnology company. |
| 2019 | Stock Listings/IPO | In November, the company raised US$60 million in an initial public offering of shares. |
Competitor Comparison
| Key Parameters | Galera Therapeutics Inc | Gilead Sciences Ltd | Arrakis Therapeutics Inc | Enzychem Lifesciences USA, Inc | EpicentRx Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
| City | Malvern | London | Waltham | - | San Diego |
| State/Province | Pennsylvania | England | Massachusetts | - | California |
| No. of Employees | 3 | 195 | - | - | - |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| J. Mel Sorensen, M.D. | Chairman; Chief Executive Officer; President | Executive Board | 2025 | 68 |
| Joel Sussman | Treasurer; Secretary; Chief Accounting Officer | Senior Management | 2019 | 76 |
| Michael Friedman | Director | Non Executive Board | 2024 | 47 |
| Lawrence Alleva | Director | Non Executive Board | 2019 | 75 |
| Nancy T. Chang, PhD | Director | Non Executive Board | 2024 | 75 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer